Table 1.
Patient characteristics
| Characteristics | NSCLC n = 96 n, (%) |
HNC/GC n = 92 n, (%) |
P-value |
|---|---|---|---|
| Age, years | |||
| Median (range) | 68 (44–80) | 67 (24–85) | 0.46 |
| < 65 | 33 (34.4) | 38 (41.3) | |
| ≥ 65 | 63 (65.6) | 54 (58.7) | |
| Sex | 0.98 | ||
| Male | 68 (70.8) | 65 (70.7) | |
| Female | 28 (29.2) | 27 (29.3) | |
| Smoking status | 0.40 | ||
| Current/ex-smoker | 75 (78.1) | 67 (72.8) | |
| Current smoker | 5 (5.2) | 11 (12.0) | |
| Ex-smoker | 70 (72.9) | 56 (60.9) | |
| < 20 pack-years | 12 (12.5) | 18 (19.6) | |
| ≥ 20 pack-years | 63 (65.6) | 45 (48.9) | |
| Unknown pack-years | 0 | 4 (4.3) | |
| Never-smoker | 21 (21.9) | 25 (27.2) | |
| Performance status | 0.36 | ||
| 0–1 | 82 (85.4) | 74 (80.4) | |
| ≥ 2 | 14 (14.6) | 18 (19.6) | |
| Prevalence of patient comorbidities | |||
| Arterial hypertension | 30 (31.3) | 26 (28.3) | 0.65 |
| Cardiovascular disease | 5 (5.2) | 8 (8.7) | 0.35 |
| Diabetes | 11 (11.5) | 12 (13.0) | 0.74 |
| COPD | 12 (12.5) | 3 (3.3) | 0.029a |
| No. of treatment cycles of nivolumab | |||
| Median (range) | 5 (1–58) | 5 (1–25) | 0.42 |
| Pre-existing ILD on chest CT | |||
| Normal | 70 (72.9) | 78 (84.8) | 0.047 |
| Pre-existing ILD | 26 (27.1) | 14 (15.2) | |
| UIP | 6 (6.3) | 2 (2.2) | |
| Possible UIP | 3 (3.1) | 1 (1.1) | |
| Inconsistent with UIP | 17 (17.7) | 11 (12.0) | |
NSCLC non-small cell lung cancer, HNC head and neck cancer, GC gastric cancer, COPD chronic obstructive pulmonary disease, ILD interstitial lung disease, CT computed tomography, UIP usual interstitial pneumonia, a Fisher’s exact test